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Abstract
Talactoferrin alfa (also known as recombinant human lactoferrin, 
rhLF) is a novel immunomodulatory protein that has previously 
demonstrated anti-tumor properties in animal models. Following a 
successful phase I trial, it was administered orally to patients with 
metastatic renal cell carcinoma (RCC) in a phase II trial conduct-
ed at the Michael E. DeBakey Veterans Affairs Medical Center in 
Houston, Texas, among other sites. We report a case series of 4 
patients treated at our institution with very encouraging progres-
sion-free survivals, all exceeding 30 months, in order to suggest 
that this agent merits further study. These four patients with radio-
graphically progressive metastatic RCC received single-agent oral 
talactoferrin in daily doses of 9 grams, given in cycles of 2 weeks 
on/2 weeks off, until evidence of toxicity or disease progression. 
Given the small sample size and the heterogenous tumor biology 
of RCC, tumor growth rate was used as a primary endpoint so that 
each patient could serve as their own control. The agent’s effec-
tiveness was then determined through radiographic tracking of the 
tumors before, during, and after treatment, with use of the Response 
Evaluation Criteria in Solid Tumors (RECIST) protocol to follow 
target lesions. The results showed that the drug was well tolerated, 
with no occurrence of talactoferrin-related grade 3 or 4 adverse 
events or laboratory anomalies by NCI-CTEP criteria. The four pa-
tients described in the case series demonstrated very encouraging 
progression-free survivals, all exceeding 30 months. We conclude 
that decreased tumor growth rate may correlate with increased pro-
gression-free survival. Talactoferrin is a promising, well-tolerated 
agent whose clinical benefits should be evaluated in a randomized 
phase III study with a placebo control arm.
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Introduction
While radical nephrectomy offers the chance for cure in lo-
calized renal cell carcinoma, improving treatment for meta-
static renal cell carcinoma remains a hotly pursued goal in 
clinical research. The predominant clear cell subtype of this 
malignancy  is  discouragingly  resistant  to  chemotherapy 
[1]. Sharpened understanding of tumor neovascularity and 
dysregulation of hypoxia-inducible factor (HIF) [2] has led 
to promising results with therapies that target downstream 
vascular endothelial growth factor (VEGF) [3, 4]. However, 
even with increasing focus on antiangiogenic agents, efforts 
continue to develop effective and tolerable immunotherapy. 
The historical experience with interleukin-2 has shown clini-
cal efficacy at high doses but its toxicity profile can limit 
the length and intensity of its use [5]. Ideally, newer immu-
notherapeutic strategies will provide effective antitumor re-
sponses without incurring as many side effects as IL-2. 
Talactoferrin alfa (talactoferrin; TLF), a novel immuno-
modulatory agent, is a recombinant human lactoferrin (rhLF) 
purified from Aspergillus. Lactoferrin, an iron-binding gly-
coprotein, can be found throughout the body, first identified 
in breast milk [6] but also present in nasolacrimal secretions, 
bronchial and cervico-vaginal mucus, and inside the gran-
ules of phagocytes [7]. As a trigger for immunomodulation 
at the gut-associated lymphoid tissue (GALT) [8], and as a 
dendritic cell maturation agent [9, 10] lactoferrin possesses 
many potentially useful pharmacologic functions, including 
anti-tumor activity. Talactoferrin has demonstrated anti-tu-
mor activity in multiple animal models of solid tumors [11]. 
A dose-escalation trial with expansion at the optimal dose 
has already been conducted at the Michael E. DeBakey Vet-
erans Affairs Medical Center in Houston, Texas to investi-
gate the safety, tolerability, and anti-tumor activity of oral 
talactoferrin in metastatic solid tumors, including renal cell 
carcinoma (RCC) [12].
In a phase IB trial [13] and a follow-on phase II study 
[14], 16 patients with metastatic RCC, all with documented 
tumor progression during the 9 months prior to enrollment, 
were treated at our institution with single-agent oral talacto-
ferrin. Patients received oral rhLF in amounts of 4.5 grams 
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or 9 grams per day administered in two divided doses. The 
drug was given in 14-day cycles interrupted by a 14-day 
rest interval, until evidence of toxicity or disease progres-
sion. One patient switched from the 4.5-gram dosage to the 
9-gram dosage due to progression on the lower dose. Pa-
tients were requested to maintain a diary documenting con-
sumption of the study drug and any side effects they experi-
enced. Toxicities were graded according to National Cancer 
Institute common toxicity criteria [15]. Prior to entering he 
study, all patients had a complete history and physical ex-
amination,  complete  blood  cell  count,  serum  chemistries 
and electrolytes, and radiologic assessment of the measur-
able tumor mass. Subsequently, a research nurse and phy-
sician saw patients at regularly scheduled outpatient clinic 
visits. Complete blood count, serum electrolytes and chem-
istries were obtained at each visit. Tumor size progression 
was monitored through serial radiologic studies, performed 
at baseline, at 2 months, and approximately every 8 weeks 
thereafter. Target lesions were selected prospectively (prior 
to start of therapy) and followed using the Response Evalua-
tion Criteria in Solid Tumors (RECIST) [16].
We report a case series of the longest-term survivors 
from these two trials, all with progression-free survival ex-
ceeding 30 months.
Case Report
These four patients’ clinical courses are synopsized in the fol-
lowing brief narratives and additional information, including 
age and MSKCC risk score from time of post-nephrectomy 
recurrence [17], can be found in Table 1.
Case 1
This patient underwent left radical nephrectomy in 1992 for 
grade II clear cell renal cell carcinoma with extension in the 
perinephric fat but no vascular invasion, no metastases to 
lymph nodes, and no positive surgical margins. In July 2004, 
he was found to have a heterogenous soft tissue mass in the 
right paratracheal area, extending to the right hilum, along 
with scattered lung nodules; biopsy during mediastinoscopy 
confirmed metastatic clear cell RCC. He was deemed to have 
unresectable disease and was enrolled in our talactoferrin tri-
al. He began the 4.5 gm arm of the study in November 2004, 
at which time he was 66 years old. He developed progressive 
disease in June 2005 after his lesions grew 24% from base-
line. In October 2005, he crossed over to the 9 gm arm of the 
study and his disease remained stable by RECIST criteria 
for 35 months until September 2008, when he developed a 
lytic lesion in his left femur. At this point his participation in 
the study ended and he was switched to sunitinib with focal 
radiotherapy for his bone lesion. He eventually underwent 
hip replacement due to progression of the bony disease. Sub-
sequent treatments have included sorafenib, everolimus, and 
pazopanib.
Case 2 
This patient underwent left nephrectomy in 1995 for local-
ized clear cell renal cell carcinoma. In December 2002, he 
was diagnosed with recurrent disease in the left renal surgical 
bed and with metastases to both lungs. After receiving IL-2 
and interferon-α at another facility from February through 
June 2003, he initiated care at our hospital in September 
Table 1. Additional Patients’ Information
Sr. No. 1 2 3 4
Age at Entry 66 51 60 72
RhLF Dose 9 g/day 9 g/day 9 g/day 9 g/day












MSKCC Risk Low Low Low Low
Patient Status Alive after 6 years Alive after 5.5 years Alive after 7.5 years Died after 37 months
PFS (Months) 35 50 35 34
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2003, at which time he was continued on interferon-α. CT 
scans in March 2005 showed progressive disease and he was 
enrolled in the talactoferrin trial in June 2005. He remains on 
study, with progression-free survival not yet reached at 50 
months. He remained on study until August 2009, when CT 
scans documented cancer progression.  He received gamma 
knife treatment for a brain metastasis and systemic treatment 
with sunitinib followed by everolimus.
Case 3 
The patient underwent left nephrectomy in 1995 for an 18 
cm clear cell/spindle cell renal cell carcinoma that invaded 
the capsule and extended into perinephric fat. In 1998 he 
developed left flank pain and was found to have biopsy-
confirmed recurrent disease in the left renal surgical bed, as 
well as subcentimeter nodules in both lung bases. The pa-
tient was treated with IL-2 and interferon-α from 1998 to 
1999 without response, then participated in an experimental 
methionine restriction diet from 1999 to 2000, during which 
he experienced disease progression. He was enrolled in the 
talactoferrin trial from July 2003 to June 2006 with stable 
disease. In June 2006, after 35 months of progression-free 
survival, he had disease progression and was changed to er-
lotinib plus bevacizumab. He did not tolerate sunitinib and 
was subsequently treated with sorafenib, temsirolimus, and 
then pazopanib.
Case 4
This patient underwent nephrectomy in 2002 for renal cell 
carcinoma. Lung metastases were diagnosed 6 weeks post-
operatively and the patient was treated with capecitabine, 
interferon-α, gemcitabine, and thalidomide. After initial im-
Figure 1. The regression of the tumor size (longest diameters) during the first 17 months of therapy in case 4.
Figure 2. CT scans showing the reduction in size of the pulmonary metastases in case 4.
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provement, he progressed and entered the talactoferrin trial 
in August 2003. He had a partial response and then remained 
stable by RECIST criteria until July 2006. His tumor regres-
sion during the first 17 months of therapy is summarized 
graphically in Figure 1. Serial CT scans, seen in Figure 2, 
show the reduction in size of his pulmonary metastases.  The 
patient’s  cancer  later  progressed  in  the  mediastinum  and 
brain, and he expired in September, 2006.
Discussion
  
These four promising examples must be interpreted within 
the appropriate context. First of all, these cases were se-
lected for presentation from a larger pool of trial patients 
precisely because their progression-free survival was so en-
couraging. Secondly, their pre-study risk stratification, based 
upon time to post-nephrectomy recurrence, performance sta-
tus, and lack of anemia, hypercalcemia, or elevated LDH, 
was uniformly low, although they had clearly documented 
tumor progression at the time of trial enrollment. Third, ar-
rested tumor growth can occur as a part of the natural history 
of metastatic RCC. Under Gompertzian models, such time-
dependent slowing occurs as the tumor growth curve reaches 
its plateau. As such, renal cell carcinomas under surveillance 
but not treatment can demonstrate a rate of volumetric ex-
pansion  that  diminishes  with  increasing  size  [18].  None-
theless, in the three-pronged attack on renal cell carcinoma 
from the avenues of cell biology, angiogenesis, and immu-
nology, well-tolerated immunomodulatory agents have been 
elusive. We suggest that the progression-free survivals of 
these patients merit further evaluation of oral talactoferrin to 
determine its true anti-neoplastic efficacy.
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